EASD 2026: Roche’s enicepatide shows 22.7% placebo-adjusted weight loss at 48 weeks

Data ReadoutpositiveenicepatidePositive

AI Analysis

Summary

Roche presented positive 48-week data for enicepatide showing 22.7% placebo-adjusted weight loss at the EASD 2026 conference, with key opinion leaders highlighting its dual-receptor mechanism as an advancement over single-target GIP agonism.

Clinical Trial Data

Primary Endpoint

Met

Outcome Details

22.7% placebo-adjusted weight loss at 48 weeks; dual-receptor mechanism viewed as significant advancement over single-target GIP agonism

Importance:7/10

Sentiment:

0.75

obesityweight lossGIP agonistdual receptorEASD 2026

Related Companies

$RHHBY

Read the original article

Published by Clinical Trials Arena on October 2, 2026 8:18 AM

Read Original